IRIS UniCatt

Ponziani, Francesca Romana
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 4.408
NA - Nord America 4.157
AS - Asia 2.217
SA - Sud America 431
AF - Africa 39
Continente sconosciuto - Info sul continente non disponibili 14
OC - Oceania 12
Totale 11.278
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.096
DE - Germania 1.263
SE - Svezia 834
IT - Italia 819
SG - Singapore 801
CN - Cina 788
BR - Brasile 399
IE - Irlanda 293
FR - Francia 280
UA - Ucraina 238
ID - Indonesia 172
GB - Regno Unito 150
IN - India 139
FI - Finlandia 128
RU - Federazione Russa 113
TR - Turchia 64
KR - Corea 58
BE - Belgio 44
HK - Hong Kong 43
NL - Olanda 43
PL - Polonia 41
CA - Canada 40
CZ - Repubblica Ceca 27
AT - Austria 26
IR - Iran 23
CI - Costa d'Avorio 20
IQ - Iraq 17
JP - Giappone 17
ES - Italia 16
VN - Vietnam 16
CH - Svizzera 15
RO - Romania 14
PK - Pakistan 12
AE - Emirati Arabi Uniti 11
AU - Australia 11
MX - Messico 10
PE - Perù 10
EU - Europa 9
IL - Israele 9
AR - Argentina 8
EC - Ecuador 7
LT - Lituania 7
PT - Portogallo 7
GR - Grecia 6
HU - Ungheria 6
KG - Kirghizistan 6
SA - Arabia Saudita 5
TZ - Tanzania 5
AL - Albania 4
BD - Bangladesh 4
EE - Estonia 4
NO - Norvegia 4
PA - Panama 4
PH - Filippine 4
SI - Slovenia 4
UZ - Uzbekistan 4
A2 - ???statistics.table.value.countryCode.A2??? 3
CL - Cile 3
DK - Danimarca 3
EG - Egitto 3
HR - Croazia 3
LA - Repubblica Popolare Democratica del Laos 3
LU - Lussemburgo 3
MK - Macedonia 3
NP - Nepal 3
SK - Slovacchia (Repubblica Slovacca) 3
TW - Taiwan 3
ZA - Sudafrica 3
A1 - Anonimo 2
CO - Colombia 2
DO - Repubblica Dominicana 2
IM - Isola di Man 2
JO - Giordania 2
MA - Marocco 2
MD - Moldavia 2
SC - Seychelles 2
SY - Repubblica araba siriana 2
TH - Thailandia 2
AM - Armenia 1
AZ - Azerbaigian 1
BG - Bulgaria 1
BO - Bolivia 1
BY - Bielorussia 1
BZ - Belize 1
CR - Costa Rica 1
CY - Cipro 1
DZ - Algeria 1
GE - Georgia 1
GH - Ghana 1
GL - Groenlandia 1
HN - Honduras 1
KE - Kenya 1
KH - Cambogia 1
KW - Kuwait 1
KZ - Kazakistan 1
LB - Libano 1
LK - Sri Lanka 1
ME - Montenegro 1
NI - Nicaragua 1
NZ - Nuova Zelanda 1
Totale 11.276
Salva come PNG Salva come JPEG
Città #
Chandler 848
Singapore 528
Ashburn 326
Dublin 290
Rome 176
New York 175
Jakarta 166
San Mateo 150
Jacksonville 139
Cattolica 125
Milan 125
Ann Arbor 115
Wilmington 100
Boston 98
Nanjing 88
Marseille 86
Moscow 82
The Dalles 80
Chicago 76
Los Angeles 74
Princeton 72
Hefei 66
Boardman 59
Frankfurt am Main 59
Beijing 58
Nürnberg 57
Seoul 55
Helsinki 53
Munich 53
Redwood City 53
Izmir 48
Zhengzhou 45
Hyderabad 44
Brussels 43
Dearborn 43
Lawrence 42
Woodbridge 41
Hong Kong 38
Bremen 37
São Paulo 37
Houston 36
Fairfield 34
Seattle 33
Nanchang 32
Nuremberg 28
Augusta 26
Hangzhou 26
Pune 26
Guangzhou 24
San Francisco 24
Shenyang 24
Düsseldorf 23
Kraków 23
North Bergen 22
Norwalk 22
Changsha 21
Abidjan 20
Hebei 20
Lancaster 20
Lauterbourg 20
London 19
Tianjin 19
Jiaxing 18
Mountain View 18
Toronto 18
University Park 18
Paris 17
Turku 17
Shanghai 16
Brno 15
Kunming 15
Portsmouth 15
Leawood 14
Santa Clara 13
Vienna 13
Belo Horizonte 12
Redmond 12
Stockholm 12
Bexley 11
Brooklyn 11
Ottawa 11
Salt Lake City 11
Warsaw 11
Andover 10
Atlanta 10
Cambridge 10
Lappeenranta 10
Rio de Janeiro 10
Arezzo 9
Jinan 9
Lima 9
San Diego 9
Baghdad 8
Buffalo 8
Esslingen am Neckar 8
Fremont 8
Kish 8
Amsterdam 7
Falkenstein 7
Las Vegas 7
Totale 5.837
Salva come PNG Salva come JPEG
Nome #
From small nodule to overt HCC: a multistep process of carcinogenesis as seen during surveillance 293
Portal vein thrombosis: insight into physiopathology, diagnosis, and treatment 291
HepPar1-Positive Circulating Microparticles Are Increased in Subjects with Hepatocellular Carcinoma and Predict Early Recurrence after Liver Resection 162
Gut microbiota compositional and functional fingerprint in patients with alcohol use disorder and alcohol-associated liver disease 160
Gut Microbiota and Cardiovascular Disease: Evidence on the Metabolic and Inflammatory Background of a Complex Relationship 155
Early prediction of response to sorafenib in patients with advanced hepatocellular carcinoma: the role of dynamic contrast enhanced ultrasound 149
Effect of rifaximin on gut microbiota composition in advanced liver disease and its complications 143
Biomarkers of low-grade inflammation in primary varicose veins of the lower limbs 143
Thrombotic risk factors in patients with liver cirrhosis: correlation with MELD scoring system and portal vein thrombosis development 142
Something more to say about calcium homeostasis: the role of vitamin K2 in vascular calcification and osteoporosis 136
Early prediction of response to Sorafenib in patients with advanced hepatocellular carcinoma: the role of dynamic contrast enhanced ultrasound 131
New modalities of ultrasound-based intima-media thickness, arterial stiffness and non-coronary vascular calcifications detection to assess cardiovascular risk 125
Treatment of recurrent genotype 4 hepatitis C after liver transplantation: early virological response is predictive of sustained virological response. An AISF RECOLT-C group study 122
Diagnosis of bowel diseases: the role of imaging and ultrasonography 119
The Role of Antibiotics in Gut Microbiota Modulation: The Eubiotic Effects of Rifaximin 116
Prevention and treatment of hepatic encephalopathy: focusing on gut microbiota 114
Morphological and functional consequences of transradial coronary angiography on the radial artery: implications for its use as a bypass conduit 113
Diagnosis and treatment of small intestinal bacterial overgrowth 113
Liver transplantation in patients with alcoholic liver disease: A retrospective study 108
Use and indications of cholestyramine and bile acid sequestrants 107
Gut microbiota and metabolic syndrome 105
Treatment of genotype-1 hepatitis C recurrence after liver transplant improves survival in both sustained responders and relapsers 104
Physiology and pathophysiology of liver lipid metabolism 103
Improved gut microbiota features after the resolution of SARS‑CoV‑2 infection 100
Treatment of hepatitis C in compensated cirrhotic patients is equally effective before and after liver transplantation 99
Treatment of genotype-1 hepatitis C recurrence after liver transplant improves survival in both sustained responders and relapsers 99
TACE with degradable starch microspheres (DSM-TACE) as second-line treatment in HCC patients dismissing or ineligible for sorafenib 97
Nasopharyngeal Microbiota Profiling of SARS-CoV-2 Infected Patients 97
The metabolic and toxicological considerations for mTOR inhibitors in the treatment of hepatocarcinoma 96
Use and indications of cholestyramine and bile acid sequestrants 95
Morphological and functional consequences of transradial coronary angiography on the radial artery: implications for its use as a bypass conduit 93
Something more to say about calcium homeostasis: the role of vitamin K2 in vascular calcification and osteoporosis. 93
Intestinal barrier in human health and disease 90
Contrast-enhanced ultrasound in the short-term evaluation of hepatocellular carcinoma after locoregional treatment 88
HepatoCATT Study Group for the Multidisciplinary Management of HCC. Interventional oncology treatments for unresectable early stage HCC in patients with a high risk for intraprocedural bleeding: Is a single-step combined therapy safe and feasible? 88
Anticoagulants in cirrhotic patients: controversies and certainties in PVT management 85
Is there a role for anticoagulants in portal vein thrombosis management in cirrhotic patients? 85
Reverse time-dependent effect of alphafetoprotein and disease control on survival of patients with Barcelona Clinic Liver Cancer stage C hepatocellular carcinoma 84
Treatment of genotype-1 hepatitis C recurrence after liver transplant improves survival in both sustained responders and relapsers 83
HEPATOCATT STUDY GROUP. Critical analysis of major and ancillary features of LI-RADS v2018 in the differentiation of small (≤ 2 cm) hepatocellular carcinoma from dysplastic nodules with gadobenate dimeglumine-enhanced magnetic resonance imaging. 82
What we should know about portal vein thrombosis in cirrhotic patients: A changing perspective 81
Bridging and downstaging treatments for hepatocellular carcinoma in patients on the waiting list for liver transplantation 81
Skeletal Muscle Loss during Multikinase Inhibitors Therapy: Molecular Pathways, Clinical Implications, and Nutritional Challenges. 81
Long-term maintenance of sustained virological response in liver transplant recipients treated for recurrent hepatitis C 80
Subclinical atherosclerosis is linked to small intestinal bacterial overgrowth via vitamin K2-dependent mechanisms 80
Hepatocellular Carcinoma is Associated with Gut Microbiota Profile and Inflammation in Non-Alcoholic Fatty Liver Disease 80
Characterization of the gut-liver-muscle axis in cirrhotic patients with sarcopenia 80
Gemelli decision tree Algorithm to Predict the need for home monitoring or hospitalization of confirmed and unconfirmed COVID-19 patients (GAP-Covid19): preliminary results from a retrospective cohort study 77
Portal vein thrombosis occurrence in a cirrhotic patient during treatment with rivaroxaban 77
Diet-Induced Alterations in Gut Microbiota Composition and Function 77
Radial Artery as a Coronary Artery Bypass Conduit: 20-Year Results 76
Project for interventional Oncology LArge-database in liveR Hepatocellular carcinoma - Preliminary CT-based radiomic analysis (POLAR Liver 1.1) 74
TACE with degradable starch microspheres (DSM-TACE) as second-line treatment in HCC patients dismissing or ineligible for sorafenib 72
Effectiveness of Paritaprevir/Ritonavir/Ombitasvir/Dasabuvir in Hemodialysis Patients With Hepatitis C Virus Infection and Advanced Liver Fibrosis: Case Reports 72
Minimal Hepatic Encephalopathy is Associated with Increased Cerebral Vascular Resistance. A Transcranial Doppler Ultrasound Study 72
Contrast-enhanced ultrasound patterns of hepatocellular adenoma: an Italian multicenter experience 70
Liver involvement is not associated with mortality: results from a large cohort of SARS-CoV-2-positive patients 70
Missed linkage to care for patients who screened positive for Hepatitis C in a tertiary care centre: Results of the Telepass project 70
Morphological and functional consequences of transradial coronary angiography on the radial artery: Implications for its use as a bypass conduit 69
A novel ultrasound-based vascular calcification score (CALCS) to detect subclinical atherosclerosis 69
Effect of liver transplantation on intestinal permeability and correlation with infection episodes 69
Interventional oncology treatment for unresecable early stage HCC in patient with high risk for intraprocedural bleeding: is a single step combined therapy safe and feasible? 68
Critical analysis of major and ancillary features of LI-RADS v2018 in the differentiation of small (< 2 cm) hepatocellular carcinoma from dysplastic nodules with gadobenate dimeglumine-enhanced magnetic resonance imaging 67
Management of hepatitis C virus infection recurrence after liver transplantation: an overview 66
Intestinal Permeability and Dysbiosis in Female Patients with Recurrent Cystitis: A Pilot Study 65
Interventional oncology treatments for unresectable early stage HCC in patients with a high risk for intraprocedural bleeding: Is a single-step combined therapy safe and feasible? 65
Intestinal permeability in the pathogenesis of liver damage: From non-alcoholic fatty liver disease to liver transplantation 65
Gut Microbial, Inflammatory and Metabolic Signatures in Older People with Physical Frailty and Sarcopenia: Results from the BIOSPHERE Study 64
Personalised management of patients with hepatocellular carcinoma: a multiparametric therapeutic hierarchy concept 64
ADAMTS-13/von Willebrand factor ratio: A prognostic biomarker for portal vein thrombosis in compensated cirrhosis. A prospective observational study 63
Treatment of early stage chronic hepatitis C virus infection 62
Prognostic value of skeletal muscle mass during tyrosine kinase inhibitor (TKI) therapy in cancer patients: a systematic review and meta-analysis 62
Future of liver disease in the era of direct acting antivirals for the treatment of hepatitis C 61
Regorafenib: a promising treatment for hepatocellular carcinoma 61
The role of antiplatelet therapies on incidence and mortality of hepatocellular carcinoma 60
Diagnostic and prognostic role of circulating microparticles in hepatocellular carcinoma. 60
Esophageal microbiome signature in patients with Barrett’s esophagus and esophageal adenocarcinoma 60
Hug sign in intraprocedural cone-beam-CT to predict short-term response to combined treatment of hepatocellular carcinoma 59
Portal vein thrombosis and liver transplantation: Implications for waiting list period, surgical approach, early and late follow-up. 59
Low risk of hepatitis B virus reactivation in patients with resolved infection and chronic myeloid leukemia treated with tyrosine kinase inhibitors 59
Personalized Therapy in a Multidisciplinary Team Improves Survival in Patient with HCC: The Hepatocatt Experience 58
MetaLiverCat: the NAFLD/NASH multidisciplinary board at Fondazione Policlinico Gemelli IRCCS 58
The new era of hepatitis C treatment: still the tip of the iceberg? 58
Portal vein thrombosis in cirrhosis: Why a well-known complication is still matter of debate 58
Durvalumab: an investigational agent for unresectable hepatocellular carcinoma 58
Eubiotic properties of rifaximin: Disruption of the traditional concepts in gut microbiota modulation 57
Low risk of hepatitis B virus reactivation in patients with resolved infection and chronic myeloid leukemia treated with tyrosine kinase inhibitors 55
Gut Dysbiosis and Fecal Calprotectin Predict Response to Immune Checkpoint Inhibitors in Patients With Hepatocellular Carcinoma 55
Treatment of hepatitis C recurrence is less successful in female than in male liver transplant recipients 54
Inducing tolerability of adverse events increases sorafenib exposure and optimizes patient's outcome in advanced hepatocellular carcinoma 54
Rifaximin for the treatment of irritable bowel syndrome – a drug safety evaluation 54
How to modulate gut microbiota: diet, pre-probiotics or antibiotics? 54
Future Modulation of Gut Microbiota: From Eubiotics to FMT, Engineered Bacteria, and Phage Therapy 53
Hepatic encephalopathy 2018: A clinical practice guideline by the Italian Association for the Study of the Liver (AISF) 53
Balloon-Occluded Radiofrequency Ablation as Bridge to TACE in the Treatment of Advanced HCC with Arterioportal Shunt 52
Low risk of hepatitis B virus reactivation in patients with resolved infection and chronic myeloid leukemia treated with tyrosine kinase inhibitors 52
Advances in pharmacotherapeutics for hepatocellular carcinoma 52
High prevalence of lower limb atherosclerosis is linked with the gut–liver axis in patients with primary biliary cholangitis 51
Late reactivation of hepatitis B virus after rituximab-containing chemotherapy for mantle cell lymphoma: a case report 51
Biliary tract microbiota: A new kid on the block of liver diseases? 51
Totale 8.663
Salva come PNG Salva come JPEG
Categoria #
all - tutte 60.615
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 60.615
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202051 0 0 0 0 0 0 0 0 0 0 0 51
2020/2021676 62 54 10 57 70 34 60 10 84 62 149 24
2021/2022957 75 51 17 65 64 32 14 181 38 62 183 175
2022/20232.545 306 288 180 360 146 332 142 247 295 55 110 84
2023/20241.664 91 413 70 86 73 253 116 37 27 88 164 246
2024/20253.171 92 87 307 90 284 132 152 175 445 475 846 86
Totale 11.526